<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558700</url>
  </required_header>
  <id_info>
    <org_study_id>STU00039556</org_study_id>
    <nct_id>NCT01558700</nct_id>
  </id_info>
  <brief_title>Duloxetine in Osteoarthritis (OA) Pain</brief_title>
  <official_title>Brain Morphometries in OA Patients Treated With Duloxetine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine in people with knee Osteoarthritis (OA) if relief of pain after
      treatment with either duloxetine or placebo is associated with changes in brain anatomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study and the hypotheses to be tested arise from work done in our group evaluating brain
      cortical changes in people with chronic back pain. These studies demonstrated a loss of about
      1.5 cc of neocortical gray matter per year of living with the condition, not including gray
      matter lost due to aging. Since this original publication, more than ten studies have
      replicated this basic result, showing that distinct chronic pain conditions are associated
      with specific brain anatomical reorganization, characterized by regional decreases in grey
      matter density. Recently, other studies have shown that when chronic pain is completely
      reversed, these anatomical changes seem to at least partially reverse within the time span of
      4-12 months, providing evidence for a time window for reversal of grey matter abnormalities A
      fundamental question that arises from these recent studies is the extent of reversibility of
      the brain atrophy associated with chronic pain following continuous use of a pain-relieving
      drug. Apkarian's lab has generated strong evidence that the brain anatomy of subjects with
      osteoarthritis (OA) is dramatically different from that of healthy subjects. Given that
      recent data show that hip replacement OA reverses brain atrophy, the investigators can now
      hypothesize with greater confidence that an effective analgesic should also reverse at least
      some of the brain atrophy observed in OA. Thus, a study in patients with chronic knee OA
      treated with duloxetine provides a unique opportunity to answer this question. Since OA
      patients in this study will have a single new agent for four months, one can directly examine
      the effects of treatment in relation to progression or regression of brain atrophy. One can
      also examine whether or not a placebo, which is thought to reflect attentional and
      motivational states, affects changes in atrophy, and if so, to what extent.

      The investigators consider the brain atrophy in chronic pain to be an overall marker of the
      extent of nervous system reorganization a subject has developed while living with the
      condition. Animal models of various chronic pain conditions repeatedly provide evidence for
      this idea, showing, for example, dramatic changes in the way pain is processed in the
      periphery, the spinal cord, and at the level of individual neurons. The investigators presume
      that these changes are the same ones contributing to atrophy in human chronic pain. However,
      most of underlying mechanisms remain to be uncovered. In addition, humans suffering from
      chronic pain exhibit a large number of cognitive and emotional deficits. The investigators
      presume that these deficits are directly related to the brain atrophies discovered in chronic
      pain conditions. Unfortunately, there are no direct studies linking brain regional atrophies
      to cognitive abilities in chronic pain, although such preliminary studies are underway in
      Apkarian's lab. Thus, in addition to the answering the previous questions, the present study
      will also allow us to investigate the extent to which reversing atrophy corresponds to
      reversing plasticity at multiple levels in the nervous system, as well as whether such
      reversal also corresponds to improvements in cognitive and emotional abilities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Brain Gray Matter Volume</measure>
    <time_frame>16 weeks compared to baseline</time_frame>
    <description>The change in gray matter volume is evaluated by subtracting the volume after the treatment (week 16) to the volume before treatment (baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Magnitude</measure>
    <time_frame>16 weeks compared to baseline</time_frame>
    <description>The Western Ontario and McMaster Osteoarthritis Index (WOMAC) score change was assess by subtracting WOMAC score after treatment (week 16) to the baseline WOMAC score. WOMAC score has a range from 0 up to 96, higher score meaning worse condition. The outcome is the decrease in WOMAC scores, meaning that the higher is the decrease, the most improvement in the condition.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching capsule given once a day for a total of 17 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Matching capsule given once a day for a total of 17 weeks.</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 45-80 years

          -  ACR criteria for OA including Kellgren-Lawrence radiographic OA grades II-IV

          -  VAS pain score &gt;5/10 within 48 hrs of the phone screen and visit 1 (Screening)

          -  Knee OA for a minimum of 12 months

          -  Need for daily pain medication to manage symptoms of OA

        Exclusion Criteria:

        Currently taking MAO inhibitors or any centrally acting drug for analgesia, depression

          -  Narrow angle glaucoma

          -  Uncontrolled hypertension

          -  Co-existing inflammatory arthritis, fibromyalgia or other chronic pain state.

          -  If a female, pregnant, trying to become pregnant, or lactating

          -  Major depressive disorder

          -  Substantial alcohol use or history of significant liver disease

          -  Use of MAO inhibitors, triptans, serotonin precursors (tryptophan)

          -  Use of potent CYP1A2 inhibitors, Thioridazine, and anti-depressants

          -  Diabetes, type 1 or type 2

          -  Condition in which the Investigator believes would interfere with the subject's
             ability to comply with study instructions, or might confound the interpretation of the
             study results or put the subject at undue risk

          -  MRI safety necessitates the exclusion of subjects having one or more of the following:

               -  Metal fragments in the eye or face, or having worked previously in the metal
                  industry

               -  Implantation of any electronic devices such as (but not limited to) cardiac
                  pacemakers, cardiac, defibrillators, and cochlear implants or nerve stimulators.

               -  Surgery on the blood vessels of the brain

               -  Claustrophobia (fear of enclosed places)

               -  Piercings or tattoos

               -  More than 250 lbs in weight

               -  Obvious brain abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Schnitzer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <results_first_submitted>December 5, 2014</results_first_submitted>
  <results_first_submitted_qc>December 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2014</results_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Apkar Apkarian</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>pain</keyword>
  <keyword>brain</keyword>
  <keyword>gray matter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine</title>
          <description>Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
Duloxetine: Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Matching capsule given once a day for a total of 17 weeks.
Sugar pill: Matching capsule given once a day for a total of 17 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine</title>
          <description>Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
Duloxetine: Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Matching capsule given once a day for a total of 17 weeks.
Sugar pill: Matching capsule given once a day for a total of 17 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="4.2"/>
                    <measurement group_id="B2" value="58.9" spread="8.6"/>
                    <measurement group_id="B3" value="58.7" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Brain Gray Matter Volume</title>
        <description>The change in gray matter volume is evaluated by subtracting the volume after the treatment (week 16) to the volume before treatment (baseline)</description>
        <time_frame>16 weeks compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
Duloxetine: Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matching capsule given once a day for a total of 17 weeks.
Sugar pill: Matching capsule given once a day for a total of 17 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brain Gray Matter Volume</title>
          <description>The change in gray matter volume is evaluated by subtracting the volume after the treatment (week 16) to the volume before treatment (baseline)</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.21"/>
                    <measurement group_id="O2" value="-0.92" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Magnitude</title>
        <description>The Western Ontario and McMaster Osteoarthritis Index (WOMAC) score change was assess by subtracting WOMAC score after treatment (week 16) to the baseline WOMAC score. WOMAC score has a range from 0 up to 96, higher score meaning worse condition. The outcome is the decrease in WOMAC scores, meaning that the higher is the decrease, the most improvement in the condition.</description>
        <time_frame>16 weeks compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
Duloxetine: Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matching capsule given once a day for a total of 17 weeks.
Sugar pill: Matching capsule given once a day for a total of 17 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Magnitude</title>
          <description>The Western Ontario and McMaster Osteoarthritis Index (WOMAC) score change was assess by subtracting WOMAC score after treatment (week 16) to the baseline WOMAC score. WOMAC score has a range from 0 up to 96, higher score meaning worse condition. The outcome is the decrease in WOMAC scores, meaning that the higher is the decrease, the most improvement in the condition.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="6.1"/>
                    <measurement group_id="O2" value="8.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine</title>
          <description>Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
Duloxetine: Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Matching capsule given once a day for a total of 17 weeks.
Sugar pill: Matching capsule given once a day for a total of 17 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>worsening knee pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness, groggy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Apkar Vania Apkarian</name_or_title>
      <organization>Northwestern University</organization>
      <phone>(312) 503-0404</phone>
      <email>a-apkarian@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

